# Armata Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Armata Pharmaceuticals, Inc.). ## Overview Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing bacteriophage therapies for serious bacterial infections. Its lead programs include AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for chronic pulmonary infections caused by Pseudomonas aeruginosa. The company combines phage discovery, purification, and cGMP manufacturing capabilities at its Los Angeles-area McConnell Facility to support clinical development from early research through trial material production. Armata does not yet sell commercial products and remains dependent on clinical progress, regulatory milestones, and external funding. ## Products & services • AP-SA02 phage therapy for S. aureus bacteremia • AP-PA02 phage therapy for P. aeruginosa lung infections • Phage discovery and purification platform • cGMP clinical trial material manufacturing • Preclinical and clinical development services for phage candidates - **Clinical-stage phage therapeutics** (85%) — Investigational bacteriophage drug candidates being advanced through human trials for serious bacterial infections. - **Grant and award-funded development** (15%) — Government and consortium-funded cost reimbursement tied to specific development programs such as AP-SA02. - AP-SA02, an intravenous phage cocktail for S. aureus bacteremia - AP-PA02, a phage cocktail for chronic pulmonary P. aeruginosa infection - Proprietary phage purification methods for high-purity therapeutic candidates - Discovery-to-clinic phage R&D platform - cGMP manufacturing, testing, and release of clinical trial material - Clinical development programs for antibacterial phage therapies ## Customers Armata’s direct customers are not commercial end-users but research sponsors, clinical investigators, and ultimately healthcare systems that would adopt its therapies if approved. In the current stage, revenue is primarily grant and award revenue tied to the AP-SA02 program, reflecting support from organizations such as MTEC rather than product sales. The company’s future commercial customers would likely include hospitals, infectious disease specialists, and pulmonary care providers treating difficult-to-manage bacterial infections. Because its therapies target drug-resistant or recurrent infections, the value proposition is clinical differentiation where standard antibiotics are inadequate or poorly tolerated. - **Research sponsors and grant funders** (primary) — Organizations such as MTEC that reimburse development costs for AP-SA02 and support clinical advancement before commercialization. - **Clinical trial investigators and sites** (primary) — Hospitals and research centers in the United States and Australia that enroll patients and generate clinical evidence for the phage programs. - **Future hospital and specialist prescribers** (secondary) — Infectious disease and pulmonary specialists who would use approved phage therapies for severe bacterial infections. - **Patients with refractory bacterial infections** (secondary) — Patients with S. aureus bacteremia or chronic P. aeruginosa pulmonary disease who need alternatives to standard antibiotics. - Government and consortium sponsors funding antibacterial R&D - Clinical trial sites enrolling patients in phage studies - Hospitals and infectious disease specialists as future adopters - Pulmonologists and respiratory clinics for chronic lung infection use cases - Patients with serious, drug-resistant bacterial infections - Healthcare systems seeking alternatives to chronic antibiotic use ## Geography Armata is headquartered in Los Angeles, California, and its core research and manufacturing operations are concentrated there at the McConnell Facility. The company also ran AP-SA02 clinical sites in the United States and Australia, showing that its development footprint is international even though it remains U.S.-based. Its current business is therefore operationally centered in the United States, with trial execution extending to selected overseas sites when needed for enrollment and study design. Geography matters mainly through clinical trial access, regulatory pathways, and the ability to manufacture cGMP trial material close to development teams. - **United States** (85%) — Headquarters, R&D, manufacturing, and most clinical activity are U.S.-based. - **Australia** (15%) — AP-SA02 Phase 1b/2a study included sites in Australia. - Headquartered in Los Angeles, California - McConnell Facility supports discovery, clinic transition, and cGMP manufacturing - Clinical trial sites in the United States - Clinical trial sites in Australia for AP-SA02 - U.S.-centric operations with limited international trial exposure - Geography affects enrollment speed, regulatory coordination, and trial logistics ## Strategy Armata’s strategy is to concentrate resources on a small number of phage programs with the clearest clinical and regulatory path, especially AP-SA02 for S. aureus bacteremia. The company is using its proprietary high-purity phage manufacturing capability as a differentiator, since repeat intravenous dosing requires consistent product quality and safety. It is also building the evidence base needed for an End-of-Phase-2 discussion with the FDA and a larger definitive efficacy trial. In parallel, Armata continues to rely on non-dilutive funding and may pursue complementary acquisitions or partnerships, but the near-term priority remains advancing current candidates toward approval. - **Complete AP-SA02 clinical development** (short-term) — AP-SA02 is the most advanced program and the clearest path to a registrational strategy in a high-unmet-need infection setting. - **Demonstrate manufacturable, high-purity phage dosing** (short-term) — Repeat intravenous dosing and clinical scalability depend on reproducible purity and release processes. - **Preserve cash and secure external funding** (short-term) — The company has no product revenue and must fund ongoing R&D through grants, financing, or strategic arrangements. - **Advance AP-PA02 as a second clinical asset** (medium-term) — A second validated program would diversify the pipeline and strengthen the platform thesis for phage therapeutics. - Advance AP-SA02 toward topline data and follow-on efficacy trials - Use high-purity phage manufacturing as a technical and regulatory advantage - Build an FDA-aligned registration path through End-of-Phase-2 planning - Progress AP-PA02 based on prior clinical signal in chronic pulmonary infection - Preserve capital by focusing on a limited number of programs - Seek grants, partnerships, or in-licensing to extend the pipeline ## Risks Armata faces the classic risks of a clinical-stage biotech company: clinical trial failure, regulatory setbacks, and the possibility that its phage platform does not translate into approvable products. The company explicitly notes that it may need additional capital and that failure to secure funding could force it to delay or eliminate programs, relinquish rights, or cease operations. Its dependence on a small number of programs increases concentration risk, while manufacturing complexity for highly purified phages could affect scalability, consistency, and regulatory acceptance. More broadly, the business is exposed to competition from antibiotics, alternative anti-infective approaches, and changing investor appetite for development-stage biotechnology. - **Need for additional capital** [high] — The company has no commercial revenue and may need to raise funds to continue development, which could dilute shareholders or force program cuts. - **Clinical development failure** [high] — AP-SA02 and AP-PA02 are still investigational, and negative efficacy or safety results would materially impair the platform thesis. - **Regulatory approval uncertainty** [high] — Even promising early data may not translate into FDA agreement on a registrational path or eventual approval. - **Manufacturing and scale-up complexity** [medium] — Therapeutic phages require consistent purity and release standards, and any production issue could delay trials or commercialization. - Clinical trial risk if AP-SA02 or AP-PA02 fails to show efficacy or safety - Regulatory risk because FDA approval depends on successful late-stage data - Financing risk due to ongoing losses and no product revenue - Manufacturing and quality risk for high-purity phage production - Pipeline concentration risk from reliance on a few lead candidates - Competitive risk from antibiotics and other anti-infective technologies ## Accounting Armata’s reported results are dominated by grant and award revenue rather than product sales, so revenue recognition depends on reimbursable development costs and sponsor terms. Because the company is still in development, quarterly results can fluctuate materially with trial timing, grant activity, and the pace of R&D spending. A major accounting judgment is the fair value of the convertible loan, which can create large non-cash gains or losses and distort period-to-period comparability. Management also highlights estimates for stock-based compensation, accruals for research and development costs, lease assets and liabilities, deferred tax assets, and impairment of long-lived or intangible assets, all of which can materially affect reported losses and balance-sheet values. - **Grant and award revenue recognition** — Can cause quarter-to-quarter variability unrelated to commercial demand - **Fair value of convertible loan** — Can materially distort earnings comparability - **Research and development accruals** — Affects operating loss timing - **Stock-based compensation** — Raises reported operating expenses and affects dilution analysis - **Impairment and valuation estimates** — Could create non-cash charges if development prospects weaken - Grant and award revenue is tied to reimbursable development costs - Revenue is not product-based, so timing depends on sponsor funding and milestones - Convertible loan fair value changes can create large non-cash earnings swings - R&D accruals affect expense timing for clinical and manufacturing activities - Stock-based compensation is a meaningful non-cash operating expense - Impairment and valuation estimates matter because the company has limited operating history --- *Last updated: 2026-08-11T04:46:21.366474+00:00*